BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas 2020;49:393-407. [PMID: 32132518 DOI: 10.1097/MPA.0000000000001507] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
2 Fu L, Chen L, Li R, Xu W, Fu J, Ye X. Metabolomics studies on cachexia in patients with cancer: a scoping review protocol. BMJ Open 2022;12:e052125. [PMID: 35414542 DOI: 10.1136/bmjopen-2021-052125] [Reference Citation Analysis]
3 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cloyd JM, Hyman S, Huwig T, Monsour C, Santry H, Wills C, Tsung A, Bridges JFP. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. Support Care Cancer. 2021;29:3009-3016. [PMID: 33030596 DOI: 10.1007/s00520-020-05813-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang G, Li B, Yin X, Gao S, Shen S, Wang H, Shi X, Liu W, Zheng K, Jing W, Zhang Y, He T, Li G, Hu X, Guo S, Jin G. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Int J Surg 2022;104:106786. [PMID: 35868619 DOI: 10.1016/j.ijsu.2022.106786] [Reference Citation Analysis]
6 Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, De Vita F, Falconi M, Frassineti GL, Giommoni E, Macchini M, Malleo G, Silvestris N, Tudisco A, Vasile E, Reni M. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Crit Rev Oncol Hematol 2021;169:103571. [PMID: 34923121 DOI: 10.1016/j.critrevonc.2021.103571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Reference Citation Analysis]